The latest announcement is out from Gyre Therapeutics (GYRE).
GNI Group Ltd. has announced that its majority-owned subsidiary, Gyre Pharmaceuticals, is set to fortify its presence in the pulmonary fibrosis market by acquiring rights to Nintedanib, a generic drug and direct competitor to its own ETUARY®. This strategic move is anticipated to provide patients with more treatment options, benefit from Gyre Pharmaceuticals’ extensive sales network in the People’s Republic of China, and boost its market position. However, the company cautions investors that these forward-looking statements involve risks and uncertainties, and there’s no guarantee that the expected revenue from Nintedanib will be realized.
Find detailed analytics on GYRE stock on TipRanks’ Stock Analysis page.
